Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma
スポンサーリンク
概要
- 論文の詳細を見る
- 2003-08-01
著者
-
Tobinai Kensei
Hematology Division National Cancer Center Hospital
-
Tobinai Kensei
Hematology And Stem Cell Transplantation Division National Cancer Center Hospital
関連論文
- Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy
- Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy : case report and review of the literature
- Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma
- Diffuse large B-cell lymphoma after transformation from low-grade follicular lymphoma : morphological, immunohistochemical, and FISH analyses
- Nocardia exalbida brain abscess in a patient with follicular lymphoma
- Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
- Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
- Epstein-Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma
- Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (^Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma
- Durable Response but Prolonged Cytopenia after Cladribine Treatment in Relapsed Patients with Indolent non-Hodgkin's Lymphomas : Results of a Japanese Phase II Study
- t(11 ; 18)-Bearing Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Responding to Cladribine
- Two Entities of Precursor T-Cell Lymphoblastic Leukemia/Lymphoma Based on Radiologic and Immunophenotypic Findings
- Primary Mediastinal Large B-Cell Lymphoma : A Single-Institution Clinical Study in Japan
- EBV-Positive Burkitt Lymphoma as a Late-Onset Posttransplantion Lymphoproliferative Disorder after Allogeneic Stem Cell Transplantation
- Primary Hepatic Low-Grade B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type : A Case Report and Review of the Literature
- Successful Allogeneic Bone Marrow Transplantation in a Case of Adult Precursor B-Lymphoblastic Lymphoma
- Japanese phase II study of ^Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
- Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia : final results of Japanese multicenter cooperative study
- Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer : Japan Clinical Oncology Group study, JCOG 9208
- Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma
- B-cell lymphoma accompanying monoclonal macroglobulinemia with features suggesting marginal zone B-cell lymphoma
- Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma : Japan Clinical Oncology Group study 9004
- A Randomized Controlled Trial Investigating the Survival Benefit of Dose-Intensified Multidrug Combination Chemotherapy (LSG9) for Intermediate- or High-Grade Non-Hodgkin's Lymphoma : Japan Clinical Oncology Group Study 9002
- Re-Treatment of Relapsed Indolent B-Cell Lymphoma With Rituximab
- Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia : a single-center analysis of 47 patients
- Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
- Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
- Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab
- Treatment of Indolent Non-Hodgkin's Lymphoma with Cladribine as Single-Agent Therapy and in Combination with Mitoxantrone
- Proteasome inhibitor, bortezomib, for myeloma and lymphoma
- Inhibitory Effect of AL-3264, a New Antiallergic Agent, on the Prausnitz-Kustner Reaction and Leukotriene Production in Monkeys
- Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
- Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with
- Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma : Japan Clinical Oncology Group study (JCOG 9305)
- Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma : 7-year follow-up results
- Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
- Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
- Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy
- CHEMOTHERAPY OF ATL
- Monoclonal Antibody Therapy for B-Cell Lymphoma : Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan
- Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma
- Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine : a multicenter study
- Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma
- Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma
- Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes